4Basebio PLC
LSE:4BB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
4Basebio PLC
Accounts Receivables
4Basebio PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
4
|
4Basebio PLC
LSE:4BB
|
Accounts Receivables
£283k
|
CAGR 3-Years
83%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accounts Receivables
£74m
|
CAGR 3-Years
39%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Accounts Receivables
£96.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Accounts Receivables
£47.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
19%
|
|
4Basebio PLC
Glance View
4basebio Plc develops gene therapy technologies and solutions. The firm is engaged in developing next generation gene therapy technologies and solutions. The firm is focused on supplying therapeutic deoxyribonucleic (DNA) for gene therapies and DNA vaccines and also for providing solutions for delivery of the DNA based products to patients. The firm focuses to manufacture and supply synthetic DNA for research, therapeutic and pharmacological use. Its TruePrime DNA amplification technology is a primer free DNA amplification method using enzymes. Its Hermes is a non-viral delivery platform that can be used to deliver various payloads, ranging from DNA to small interfering ribonucleic acid (siRNA), as well as protein cargoes. The company also offers a messenger ribonucleic acid (mRNA) production service from the DNA template it makes. The company offers a range of services including production of synthetic DNA and RNA payloads, design and assembly of payloads in nanoparticles.
See Also
What is 4Basebio PLC's Accounts Receivables?
Accounts Receivables
283k
GBP
Based on the financial report for Dec 31, 2024, 4Basebio PLC's Accounts Receivables amounts to 283k GBP.
What is 4Basebio PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
30%
Over the last year, the Accounts Receivables growth was 164%. The average annual Accounts Receivables growth rates for 4Basebio PLC have been 83% over the past three years , 30% over the past five years .
